you are viewing a single comment's thread.
looks like west coast time would be 3:30 eastern so not a lot of time for things to be consumed in case some mention of gdc-0499 and pancreas cancer.
Anyone know if today's presentation is going to be available to us?
Also, don't forget INFI is supposed to reveal the overall survival numbers for their trial in pancreatic. This may have a positive impact on CRIS as well.http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=115&abstractID=88750
Link is to Timmerman's commentary on today's INFI data release.http://www.xconomy.com/boston/2012/01/20/infinity-offers-new-hint-of-effect-with-pancreatic-cancer-drug/Br'er
Many months ago I pointed out that there were four trials that would affect CRIS regarding pancreatic cancer and that timing would play a part in short-term pps of CRIS.http://clinicaltrials.gov/ct2/show/NCT01298011?term=nab-paclitaxel&cond=pancreatic+cancer&rank=9http://clinicaltrials.gov/ct2/show/NCT01130142?term=ipi+926&cond=pancreatic+cancer&rank=1http://clinicaltrials.gov/ct2/show/NCT01195415?term=gdc-0449+and+pancreatic+cancer&cond=pancreatic+cancer&rank=3http://clinicaltrials.gov/ct2/show/NCT01088815?term=gdc-0449+and+pancreatic+cancer&cond=pancreatic+cancer&rank=4My research and Dr's Von Hoff and Thompson's presentations lead me to believe that the last listed may lead to the best overall results.